CA2090688A1 - Regulation de la proliferation des cellules neoplasiques a l'aide d'un nouveau recepteur 5htla - Google Patents

Regulation de la proliferation des cellules neoplasiques a l'aide d'un nouveau recepteur 5htla

Info

Publication number
CA2090688A1
CA2090688A1 CA002090688A CA2090688A CA2090688A1 CA 2090688 A1 CA2090688 A1 CA 2090688A1 CA 002090688 A CA002090688 A CA 002090688A CA 2090688 A CA2090688 A CA 2090688A CA 2090688 A1 CA2090688 A1 CA 2090688A1
Authority
CA
Canada
Prior art keywords
cells
receptor
cell
proliferation
receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002090688A
Other languages
English (en)
Inventor
Thomas Martin Aune
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2090688A1 publication Critical patent/CA2090688A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002090688A 1990-09-04 1991-09-04 Regulation de la proliferation des cellules neoplasiques a l'aide d'un nouveau recepteur 5htla Abandoned CA2090688A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57871090A 1990-09-04 1990-09-04
US578,710 1990-09-04

Publications (1)

Publication Number Publication Date
CA2090688A1 true CA2090688A1 (fr) 1992-03-05

Family

ID=24313971

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002090688A Abandoned CA2090688A1 (fr) 1990-09-04 1991-09-04 Regulation de la proliferation des cellules neoplasiques a l'aide d'un nouveau recepteur 5htla
CA002090689A Abandoned CA2090689A1 (fr) 1990-09-04 1991-09-04 Regulation de la proliferation des cellules t au moyen d'un nouveau recepteur 5htla

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002090689A Abandoned CA2090689A1 (fr) 1990-09-04 1991-09-04 Regulation de la proliferation des cellules t au moyen d'un nouveau recepteur 5htla

Country Status (5)

Country Link
EP (2) EP0555231A1 (fr)
JP (2) JPH06503816A (fr)
AU (2) AU8848291A (fr)
CA (2) CA2090688A1 (fr)
WO (2) WO1992004015A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411960A (en) * 1993-12-09 1995-05-02 Bayer Aktiengesellschaft Substituted pyrroloanthracenes and -diones
US5461054A (en) * 1993-12-09 1995-10-24 Bayer Aktiengesellschaft Anthracene-spiro-pyrrolindines
US5409932A (en) * 1993-12-09 1995-04-25 Bayer Ag Piperazine-substituted pyrroloanthracenes
WO1996001107A1 (fr) * 1994-07-06 1996-01-18 Bo Arne Hofmann Emploi d'agents pharmaceutiques retablissant, ameliorant ou traitant la deficience immunitaire et notamment ameliorant ou traitant certains troubles immunitaires lies a des infections par le vih
AU2880495A (en) * 1994-07-06 1996-01-25 Bo Arne Hofmann Use of pharmaceutical agents for alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
EP0813878B1 (fr) * 1996-06-17 2002-02-06 Mitsubishi Chemical Corporation Agent pour accélérer la lacrimation contenant un ligand de la sérotonine, particuliérement un composé aminoalkoxybibenzyle
CA2443050A1 (fr) 2001-03-30 2002-10-10 Philadelphia Health And Education Corporation Immunomodulation et action sur des processus cellulaires relatifs aux recepteurs de la famille de la serotonine
EP2420239B1 (fr) * 2007-04-13 2015-01-14 Southern Research Institute Clomipramine comme agent anti-angiogénique
CN113599370B (zh) * 2021-08-03 2023-12-08 复旦大学附属肿瘤医院 8-oh-dpat及其衍生物在制备抗肿瘤药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05502217A (ja) * 1989-08-21 1993-04-22 ベス　イスラエル　ホスピタル　アソシエーション セロトニン拮抗薬の局所用調製物を使用した、皮膚、眼、および粘膜の過敏症、炎症、および過増殖状態の治療のための方法および組成物

Also Published As

Publication number Publication date
WO1992004015A3 (fr) 1992-04-16
WO1992004015A2 (fr) 1992-03-19
AU8499891A (en) 1992-03-30
JPH06503816A (ja) 1994-04-28
WO1992004014A2 (fr) 1992-03-19
AU8848291A (en) 1992-03-30
JPH06500775A (ja) 1994-01-27
CA2090689A1 (fr) 1992-03-05
EP0555231A1 (fr) 1993-08-18
EP0547172A1 (fr) 1993-06-23
WO1992004014A3 (fr) 1992-05-14

Similar Documents

Publication Publication Date Title
Monti Serotonin control of sleep-wake behavior
Hu et al. Lesions of the nigrostriatal dopamine projection increase the inhibitory effects of D1 and D2 dopamine agonists on caudate-putamen neurons and relieve D2 receptors from the necessity of D1 receptor stimulation
Nakajima et al. Role of tumor necrosis factor-α in methamphetamine-induced drug dependence and neurotoxicity
Shopsin et al. Parachlorophenylalanine reversal of tranylcypromine effects in depressed patients
Karschin et al. The interaction of agonists and noncompetitive antagonists at the excitatory amino acid receptors in rat retinal ganglion cells in vitro
Diana et al. Enduring effects of chronic ethanol in the CNS: basis for alcoholism
CA2331070A1 (fr) Nouvelle utilisation
EP1778245A2 (fr) Bloqueurs de canal calcique de type t et traitement de maladies
Ennis et al. Neurochemistry of the main olfactory system
CA2090688A1 (fr) Regulation de la proliferation des cellules neoplasiques a l'aide d'un nouveau recepteur 5htla
Wang et al. Noradrenergic lesion of the locus coeruleus increases the firing activity of the medial prefrontal cortex pyramidal neurons and the role of α2-adrenoceptors in normal and medial forebrain bundle lesioned rats
AU2005247409B2 (en) Treating seizures using ICE inhibitors
AU2002305123B2 (en) Immunomodulation and effect on cell processes relating to serotonin family receptors
Ferreira et al. Ionotropic glutamate receptor subunit expression in the rat hippocampus: lack of an effect of a long‐term ethanol exposure paradigm
Fischer et al. Anticonvulsant and sodium channel blocking activity of higher doses of clenbuterol
Kimmel et al. Synergism between buprenorphine and cocaine on the rotational behavior of the nigrally-lesioned rat
Szabò et al. Regulation of Kv1. 3 during Fas-induced apoptosis
Śmiałowski et al. Repeated imipramine treatment increases the responsivity of the rat hippocampus to dopamine. An in vitro study
신재진 PV-dependent adenylate cyclase 5 signaling mediates regulation of excitatory synapses of parvalbumin interneuron for auditory sensorimotor gating
WO2007019880A1 (fr) Utilisation d'un inhibiteur sélectif du recaptage de la norépinéphrine pour traiter des troubles respiratoires qui résultent du syndrome de rett
Andreou Involvement of kainate glutamate receptors in the modulation of neuronal transmission in brain areas involved in migraine pathophysiology
Rodger The anticonvulsant profiles of two calcium channel antagonists in animal models of epilepsy
Gillan et al. 100 nM each of unlabelled [D-Ala2, MePhe4, Gly-ol5] enkephalin and [D-Ala% 2D-Leu5]
Posner Novel melatonin MT1 receptor agonists as antidepressants: In vivo electrophysiological and behavioural characterization
Sumali et al. THE IMMUNOMODULATORY EFFECT OF ENDURANCE EXERCISE (EE) AND RESISTANCE EXERCISE (RE) ON HEALTHY AND CANCER SUBJECT THROUGH THE KYNURENINE PATHWAY

Legal Events

Date Code Title Description
FZDE Dead